ClinicalTrials.Veeva

Menu

Intranasal Fentanyl for Pain Management

G

Genesys

Status and phase

Unknown
Phase 4

Conditions

Trauma
Pain

Treatments

Drug: intra-nasal fentanyl
Drug: intravenous fentanyl

Study type

Interventional

Funder types

Other

Identifiers

NCT00882960
104904-1

Details and patient eligibility

About

Goal of the research will be to demonstrate a reduction in reported pain following the atomization and intra-nasal administration of Fentanyl versus the reduction in pain achieved from intravenous Fentanyl. It is hypothesized that pain should be reduced following fentanyl administration using the intra-nasal atomization equal to the intravenous delivery.

Full description

Currently, pre-hospital providers have the ability to administer analgesia to patients through only intravenous routes. Often times patients have been exposed to the elements, present with poor anatomy, or are in such a position that makes establishing intravenous impractical or impossible. The lack of delivery method than prevents the patients from receiving humane and indicated pain medication. In patients who access is achieved, they are first subjected to a painful procedure that often will be repeated within twenty-four hours by most hospital policies and than subjects them to potential infection risk, being often times in less than aseptic conditions.

The goal of the study will be to test the method of administration of pain medication using atomization through an intra-nasal route as compared to the current standard of drug administration intravenous. The medication to be administered will be Fentanyl, a previously established and approved pre-hospital analgesic medication. As with any drug there are potential risks associated with unknown side effects or allergies, the risk would not be enhanced given the use of a different delivery device. Specific risks associated with the use of this delivery route would include but not be limited to potential soft tissue injuries, epistaxis, and aspiration

The study will measure reduction in pain following the delivery of atomized fentanyl via intra-nasal administration as compared with intravenous. We will ask participants to quantify their pain using the Wong-Baker FACES pain scale (previously established valid instrument of pain assessment) and assign a number to the pain they are feeling. The drug will than be administered using the atomizer and two subsequent reports of pain using the same scale will be taken along with vital signs.

Enrollment

500 estimated patients

Sex

All

Ages

14+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Persons who meet the current State of Michigan County of Oakland and County of Genesee pre-hospital pain requiring analgesia.
  • Examples of these patients would be those with fractures, kidney stones, or traumatic injuries, burns.

Exclusion criteria

  • Patients who have compromised nasal pharynx such as those who have obvious fractures or epistaxis.
  • Additionally patients who are in the supine position for cervical spine immobilization will be excluded.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

500 participants in 2 patient groups

1
Active Comparator group
Description:
patients who are randomized to receive intravenous fentanyl for control of their pain
Treatment:
Drug: intravenous fentanyl
2
Active Comparator group
Description:
patients who are randomized to receive intra-nasal fentanyl for control of their pain
Treatment:
Drug: intra-nasal fentanyl

Trial contacts and locations

1

Loading...

Central trial contact

Ryan P Kirby, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems